Report for: Efficacy and safety of nitazoxanide plus atazanavir/ritonavir for the treatment of moderate to severe COVID-19 (NACOVID): A structured summary of a study protocol for a randomised controlled trial

Title	Efficacy and safety of nitazoxanide plus atazanavir/ritonavir for the treatment of moderate to severe COVID-19 (NACOVID): A structured summary of a study protocol for a randomised controlled trial
Published in	Trials, January 2021
DOI	10.1186/s13063-020-04987-8
Pubmed ID	33397457
Authors	Adeniyi Olagunju, Adeola Fowotade, Ajibola Olagunoye, Temitope Olumuyiwa Ojo, Bolanle Olufunlola Adefuye, Adeniyi Francis Fagbamigbe, Akindele Olupelumi Adebiyi, Omobolanle Ibitayo Olagunju, Olabode Taiwo Ladipo, Abdulafeez Akinloye, Babatunde Ayodeji Adeagbo, Adedeji Onayade, Oluseye Oladotun Bolaji, Christian Happi, Steve Rannard, Andrew Owen

X Demographics

The data shown below were collected from the profiles of 8 X users who shared this research output. Click here to find out more about how the information was compiled.

Type	Count	As %
Members of the public	5	63%
Scientists	2	25%
Practitioners (doctors, other healthcare professionals)	1	13%

Mendeley readers

The data shown below were compiled from readership statistics for 177 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Country	Count	As %
Unknown	177	100%

Readers by professional status	Count	As %
Student > Bachelor	25	14%
Student > Master	20	11%
Researcher	16	9%
Student > Ph. D. Student	13	7%
Other	8	5%
Other	26	15%
Unknown	69	39%

Readers by discipline	Count	As %
Medicine and Dentistry	48	27%
Nursing and Health Professions	21	12%
Pharmacology, Toxicology and Pharmaceutical Science	15	8%
Psychology	4	2%
Agricultural and Biological Sciences	3	2%
Other	17	10%
Unknown	69	39%

Efficacy and safety of nitazoxanide plus atazanavir/ritonavir for the treatment of moderate to severe COVID-19 (NACOVID): A structured summary of a study protocol for a randomised controlled trial